Assessment of Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Dermoscopy
Evaluation of Morphological Findings Related to Activity, Stability, and Repigmentation in Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Fluorescence Dermoscopy: A Cross-Sectional Observational Imaging Study
The goal of this observational study is to learn how different close-up skin imaging methods show vitiligo spots in adults with vitiligo. The study will look at skin changes that may be related to whether a vitiligo spot is active, stable, or gaining color again.
The main question it aims to answer is: Can special light-based imaging methods show useful details of vitiligo spots differently than regular polarized dermoscopy?
Participants will have vitiligo spots photographed during one study visit. Researchers will take images using polarized dermoscopy, sub-ultraviolet reflectance imaging, and ultraviolet fluorescence dermoscopy. Dermatologists will later review the coded images and score how clearly selected skin features can be seen.
The study will not change participants' treatment. It will not include blood tests, biopsy, injections, or any other invasive procedure.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Description détaillée
This is a single-center, cross-sectional observational imaging study in patients with clinically diagnosed vitiligo.
During a single study visit, demographic and clinical information will be recorded, including disease duration, recent disease course, current treatment status, and patient-reported changes in selected lesions. One to three clinically suitable vitiligo lesions will be included in the main assessment dataset for each participant. Genital lesions will not be evaluated due to practical imaging limitations, hygiene considerations, and participant comfort.
Each selected lesion will be imaged using the Casio DZ-D100-AEA device, which allows simultaneous acquisition of digital contact polarized dermoscopy, digital contact non-polarized dermoscopy, and sub-ultraviolet reflectance dermoscopy images from the same lesion area with a single image capture. This approach is intended to improve within-lesion comparability between polarized dermoscopy and sub-ultraviolet reflectance dermoscopy. Non-polarized images will be obtained as an automatic device output but will not be included in the routine analysis. Ultraviolet fluorescence dermoscopy images will be obtained from the same selected lesion using the DermLite DL5 handheld ultraviolet dermoscope with a smartphone adapter.
For each participant, one lesion will be designated as the index lesion for the primary analysis. If available, the second and third lesions in the main assessment dataset may be used for secondary and exploratory analyses. In participants with more than three imaged lesions, additional lesion images beyond the lesions retained in the main assessment dataset will be assigned to a separate exploratory/calibration image pool and will not be included in the formal main assessment dataset.
The allocation of lesions to the main assessment dataset or the exploratory/calibration pool will be completed before formal image scoring. When more than three lesions are available from a participant, lesions with clearer recent clinical history regarding activity, stability, or repigmentation will be preferentially retained in the main assessment dataset. If several lesions have similarly clear clinical information, allocation will aim to preserve representation of active/progressive, stable, and repigmented/regressive lesions when possible.
The exploratory/calibration image pool will be used for initial exploratory review, refinement of morphological terminology, preparation of evaluator training material, and calibration of scoring rules. These images will not be used as confirmatory evidence for the primary analysis.
Morphological assessment items will be developed from the literature and refined through the calibration process. This process will be used to standardize terminology and scoring rules among dermatologist evaluators before formal image evaluation.
After the scoring form is finalized, coded images from the main assessment dataset will be evaluated by dermatologist evaluators using a 0-3 visibility scoring system. To reduce observer bias, images will be presented without participant identity, lesion code, clinical lesion category, treatment information, or clinical history.
Complete blinding to imaging modality may not be possible because the imaging modalities have characteristic color and light features. This will be considered a methodological limitation. However, the coded and randomized image review process is intended to reduce recognition bias, recall bias, and assessment-order bias.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Sueda Şanlı Arıkan, Dermatology Resident Physician
- Numéro de téléphone: +90 5362483355
- E-mail: sueda.sanli.md@gmail.com
Lieux d'étude
-
-
-
Istanbul, Turquie (Türkiye)
- Recrutement
- University of Health Sciences Istanbul Training and Research Hospital
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adult patients with clinically diagnosed vitiligo who attend the dermatology outpatient clinic and have at least one clinically suitable non-genital vitiligo lesion for dermoscopic imaging.
La description
Inclusion Criteria:
- Adults aged 18 years or older
- Clinical diagnosis of vitiligo
- Presence of at least one clinically suitable non-genital vitiligo lesion for dermoscopic imaging
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Uncertain clinical diagnosis of vitiligo or presence of another hypopigmented or depigmented disorder that may interfere with lesion evaluation
- Absence of any clinically suitable non-genital vitiligo lesion for imaging
- Inability to cooperate with the imaging procedure
- Refusal or inability to provide written informed consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_ONLY
- Perspectives temporelles: CROSS_SECTIONAL
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
|---|
|
Adults With Vitiligo
Adult participants with clinically diagnosed vitiligo who will undergo close-up dermoscopic imaging of one to three clinically suitable vitiligo lesions during a single study visit |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Comparison of total visibility scores between polarized dermoscopy and sub-ultraviolet reflectance dermoscopy
Délai: Day 1
|
For each participant, the index lesion will be evaluated in polarized dermoscopy and sub-ultraviolet reflectance dermoscopy images. Selected lesion morphology items on the finalized scoring form will be scored from 0 to 3, where 0 indicates absent or not visible and 3 indicates clearly visible. A total visibility score will be calculated for each modality, and the paired within-lesion difference between the two modalities will be analyzed. |
Day 1
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Visibility scores of individual lesion morphology items across imaging modalities
Délai: Day 1
|
Individual lesion morphology items on the finalized scoring form will be evaluated using a 0-3 visibility scoring system, where 0 indicates absent or not visible and 3 indicates clearly visible. Scores will be assessed across polarized dermoscopy, sub-ultraviolet reflectance dermoscopy, and ultraviolet fluorescence dermoscopy. |
Day 1
|
|
Detection rates of individual lesion morphology items after dichotomization of visibility scores
Délai: Day 1
|
Visibility scores will be dichotomized for each lesion morphology item, with a score of 0 defined as not detected and scores of 1, 2, or 3 defined as detected. Detection rates will be calculated and compared across imaging modalities. |
Day 1
|
|
Assessment of ultraviolet and sub-ultraviolet optical findings
Délai: Day 1
|
Optical findings observed in sub-ultraviolet reflectance dermoscopy and ultraviolet fluorescence dermoscopy will be assessed using the finalized scoring form. Depending on the finalized assessment item, findings may be recorded either as 0-3 visibility scores or as binary detection variables. These findings may include lesion-to-surrounding skin contrast, border visibility, perifollicular optical changes, and intralesional heterogeneity. |
Day 1
|
|
Inter-rater agreement for lesion morphology assessment
Délai: Through completion of image evaluation, up to 6 months
|
Agreement between dermatologist evaluators will be assessed for visibility scores and/or binary detection of lesion morphology items using appropriate agreement statistics. |
Through completion of image evaluation, up to 6 months
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chaise d'étude: Ayşe Esra Koku Aksu, Professor, University of Health Sciences Istanbul Training and Research Hospital, Dermatology Department
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- IstanbulTRH-DERM-VITSUV-2026
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .